We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04003207
Recruitment Status : Completed
First Posted : July 1, 2019
Last Update Posted : June 12, 2020
Information provided by (Responsible Party):
Swathi Sethuram, Icahn School of Medicine at Mount Sinai

Brief Summary:
Phelan McDermid syndrome (PMS) is a rare genetic form of autism spectrum disorder (ASD) due to deletions or mutations in the SHANK3 gene. This is a pilot open labeled trial of growth hormone therapy in children with PMS targeting social withdrawal and repetitive behavior. This research study will include children with PMS between 2-12 years of age who will receive growth hormone daily for 12 weeks, if found to be eligible. The aim of this study is to evaluate the effect of growth hormone on behavioral outcomes such as the aberrant behavior checklist social withdrawal subscale (ABC-SW) and repetitive behavior scale- revised (RBS-R). The effects of growth hormone on visual evoked potentials will also be assessed. Growth hormone increases insulin like growth factor 1 (IGF-1) levels and a previous trial of IGF-1 therapy in PMS children showed improvement in these behavioral scales. Growth hormone has been studied for decades with an excellent safety profile and fewer adverse effects compared to IGF-1 therapy in other conditions. Hence, this may be a viable therapeutic option. There is no treatment currently available for PMS and this trial is therefore extremely important.

Condition or disease Intervention/treatment Phase
Phelan McDermid Syndrome Drug: Recombinant human Growth hormone Phase 2

Detailed Description:

BACKGROUND: Phelan-McDermid syndrome (PMS) is a genetic form of autism spectrum disorder (ASD) associated with developmental delay and hypotonia. IGF-1 promotes brain vessel growth, neurogenesis, and synaptogenesis.

The research team previous clinical trial of IGF-1 in patients with Phelan McDermid Syndrome has shown improvement in core ASD symptoms using the Aberrant Behavior Checklist (ABC) and the Repetitive Behavior Scale-Revised (RBS-R). Growth hormone (GH) binds to its receptor and initiates a cascade of events which directly increases synthesis and release of IGF-1 levels. HYPOTHESIS: The study team hypothesize that rise in IGF-1 stimulated by growth hormone (GH) administration should produce improvement in behavior in children and adolescents with PMS as previously demonstrated with use of IGF-1.

RESEARCH PLAN: The study team seek to recruit 10 patients with PMS and administer growth hormone as once daily subcutaneous injections for 12 weeks at standard doses. The study team will monitor baseline anthropometric measures, laboratory parameters for growth, IGF-1 levels, and bone age prior to therapy and continue to monitor safety laboratory parameters during and after therapy. The goal of therapy would be to maintain IGF-1 levels between 1-2SD above the mean for age and puberty. Evaluations will include validated behavioral scales. Visual evoked potentials (VEPs) will be used as biomarkers of visual sensory reactivity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Trial of Growth Hormone in Children and Adolescents With Phelan-McDermid Syndrome Targeting Social Withdrawal
Actual Study Start Date : September 13, 2019
Actual Primary Completion Date : June 5, 2020
Actual Study Completion Date : June 5, 2020

Arm Intervention/treatment
Experimental: Phelan-McDermid syndrome
Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy
Drug: Recombinant human Growth hormone
Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.

Primary Outcome Measures :
  1. ABC - Social Withdrawal subscale [ Time Frame: After 12 weeks of growth hormone therapy ]
    A caregiver report symptom checklist. 58-item instrument into 5 subscales: Irritability (score 0-45); Lethargy/Social Withdrawal (score 0-48); Stereotypic Behavior (score 0-21); Hyperactivity (score 0-48); Inappropriate Speech (score 0-12). Total scale 0-174, with higher score indicating more aberrant behavior.

  2. Repetitive Behavior Scale-Revised (RBS-R) [ Time Frame: After 12 weeks of growth hormone therapy ]
    A 43 item instrument with total score from 0-129, with higher score indicating more restricted, repetitive and stereotyped behaviors.

  3. The Sensory Profile [ Time Frame: After 12 weeks of growth hormone therapy ]
    The full Sensory Profile has 125 items and the short version contains 38 items. Irritability; Lethargy/Social Withdrawal; Stereotypic Behavior; Hyperactivity; Inappropriate Speech. Parents use a Likert scale to rate how frequently their child demonstrates a particular behavior (ranging from 1 = always to 5 = never). Total scale for the Short Sensory Profile 38-190, with a lower score indicates greater deviation from typically developing children and indicates more sensory reactivity symptoms.

  4. The Sensory Assessment for Neurodevelopmental Disorders (SAND) [ Time Frame: After 12 weeks of growth hormone therapy ]
    a clinician-administered assessment and corresponding caregiver interview that is not dependent on verbal or cognitive ability and is therefore appropriate for severely affected or nonverbal individuals with PMS. Responses are rated by a trained examiner on an algorithm. Scores are dichotomous, 0 (not present) or 1 (present) and are based on a summary of observed sensory behaviors throughout the duration of the observation. A total SAND score ranging from 0 to 90. Higher scores represent a higher level of sensory reactivity symptoms.

Secondary Outcome Measures :
  1. Visual evoked potentials (VEP) [ Time Frame: After 12 weeks of growth hormone therapy ]
    A noninvasive technique to evaluate the functional integrity of visual pathways in the brain from the retina to the visual cortex via the optic nerve/optic radiations. The VEP is recorded from the head's surface, over the visual cortex, and is extracted from ongoing EEG through signal averaging. VEPs reflect the sum of excitatory and inhibitory postsynaptic potentials occurring on apical dendrites (Zemon et al., 1986) which modulate excitatory and inhibitory signals received by the pyramidal cells.

  2. Change in Auditory event related potentials (AERP) [ Time Frame: Baseline and 12 weeks of growth hormone therapy ]
    AERP is useful for characterizing early processing of auditory tones and habituation to rapidly repeated stimuli as in speech processing. AERP amplitudes are measured at 12 weeks and compared to baseline.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Known pathogenic deletions or mutations in SHANK3 gene diagnosed by array CGH and/or direct sequencing.
  • Children between 2 and 12 years of age.
  • Open epiphyses on bone age x ray

Exclusion Criteria:

  • closed epiphyses;
  • active or suspected neoplasia;
  • intracranial hypertension;
  • hepatic insufficiency;
  • renal insufficiency;
  • cardiomegaly/valvulopathy;
  • history of allergy to growth hormone or any component of the formulation (mecasermin);
  • history of extreme prematurity (<1000 grams) with associated early neo-natal complications, e.g. intra-cerebral
  • hemorrhage, prolonged hypoxia, prolonged hypoglycemia;
  • patients with comorbid conditions who are deemed too medically compromised to tolerate the risk of experimental treatment with growth hormone.
  • Patient with visual problems that preclude the use of VEP's

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04003207

Layout table for location information
United States, New York
Seaver Autism Center
New York, New York, United States, 10029
Sponsors and Collaborators
Swathi Sethuram
Layout table for investigator information
Principal Investigator: Swathi Sethuram, MD Icahn School of Medicine at Mount Sinai
Study Director: Alexander Kolevzon, MD Icahn School of Medicine at Mount Sinai
Study Director: Robert Rapaport, MD Icahn School of Medicine at Mount Sinai

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Swathi Sethuram, Fellow, Division of Pediatric Endocrinology & Diabetes, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT04003207    
Other Study ID Numbers: GCO 18-2549
First Posted: July 1, 2019    Key Record Dates
Last Update Posted: June 12, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Swathi Sethuram, Icahn School of Medicine at Mount Sinai:
Phelan McDermid Syndrome
22q13 deletion Syndrome
Growth hormone
Insulin like growth factor 1
Additional relevant MeSH terms:
Layout table for MeSH terms
Chromosome Disorders
Chromosome Deletion
Pathologic Processes
Chromosome Aberrations
Congenital Abnormalities
Genetic Diseases, Inborn
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs